

6th January, 2025

# **MOS** **MARKET** **ROUNDUP**



**Nifty : 23,616.05 -388.70 (-1.62%)**

**Sensex : 77,964.99 -1258.12 (-1.59%)**

- The equity benchmark Nifty plunged nearly 400 points, while the Sensex tumbled over 1200 points, driven by weak sentiment in global markets and anticipation of IT giant TCS's upcoming quarterly results. Market sentiment was further dampened by reports of the first human metapneumovirus (HMPV) case detected in Bengaluru and a new virus outbreak in China. Investors remained cautious ahead of the inauguration of the new U.S. President on January 20 and concerns over foreign institutional investors (FIIs) continuing to sell. FIIs were net sellers, offloading over Rs 4,000 crore in the previous session. The India VIX, a volatility index that measures market fear, surged 15% to close at 15.65 as a broad-based sell-off hit mid and small-cap stocks across multiple sectors. Sensex nosedived by 1258 points or 1.6% to close nearly day's low at 77,964, while the Nifty fell 388 points or 1.6% to close at 23616. Most sectors faced heavy losses, with PSU banks, real estate, cement, auto, and oil & gas stocks among the worst performers. The Nifty PSU Bank Index fell 4%, pressured by weak quarterly updates from Union Bank, PNB, and Bank of Baroda. Union Bank saw a 7.5% decline to Rs 114.72, while Bank of Baroda, Bank of India, IOB, PNB, and Central Bank of India posted losses ranging from 4% to 6%. In contrast, diagnostic stocks rallied after news of a rapidly spreading HMPV outbreak in China, reminiscent of the early days of the COVID-19 pandemic. Thyrocare soared over 11% to close at Rs 1,017, while Metropolis, Dr. Lal PathLabs, Vijay Diagnostic, and Apollo Hospitals posted gains of up to 2%. Global markets remained mixed, with Asian and European indices reflecting uncertainty amid concerns over China's slowing economy, U.S. interest rate expectations, and geopolitical tensions in Ukraine and the Middle East.

### Technical Outlook:

- Nifty index opened flattish and cascaded right from the start of the session and gave up the gains of the last three sessions. Bears had complete control and dropped to 23550 zones by 390 points. It formed a big bearish candle on daily frame and closed with losses of around 420 points. Now till it holds below 23800 zones, weakness could be seen towards 23550 then 23450 zones while hurdles are placed at 23800 then 24000 zones.

### Derivative Outlook:

- Nifty future closed negative with losses of 1.50% at 23730 levels. Positive setup seen in Godrej Consumer Products, Dr. Lal path labs, Apollo Hospital, Abbot India, Tata Consumer products, Jubilant Food works, SBI Cards, Titan, Granules India and HCL Tech while weakness in SJVN, HFCL, CESC, HPCL, NCC, Adani Green, Hind Copper, MCX, IRFC and JSW Energy.
- On option front, Maximum Call OI is at 25000 then 24500 strike while Maximum Put OI is at 23000 then 22500 strike. Call writing is seen at 24000 then 24200 strike while Put writing is seen at 23300 then 23000 strike. Option data suggests a broader trading range in between 23200 to 24200 zones while an immediate range between 23400 to 23900 levels.

- Titan 3Q Sales Rise 24% Y/y on Festive Demand – Company's third-quarter revenue rose about 24%, boosted by strong jewelry demand during the festive season. Gold sales grew 24% on preference for the metal as an investment avenue, Titan said Company saw high single-digit growth in number of jewelry buyers and double-digit increase in ticket sizes, aided by Diwali festival
- Jubilant Foodworks 3Q revenue grows 56.2% YoY – Company's consolidated revenue for the quarter ended December was Rs2150, up 56.2% from a year earlier. Domino's India saw like-for-like growth of 12.5%
- Group added 130 stores during the quarter, reaching total 3,260 stores.
- Services PMI Rises To Four-Month High Of 59.3 In December – Service PMI during the month of December at 59.3 against 58.4 previous month. Composite PMI at 59.2 vs 60.7 previous year
- Metropolis Health business - Q3 Revenue Jumps 11% (YoY) – Company saw an 11% jump in revenue for the quarter ended December, driven by patients and tests volume growth. B2C revenue grew 15% YoY, while Truhealth wellness and bundling segment saw 25% growth. Overall revenue growth was affected by a decline in the institutional business. Company said it is debt-free with Rs200cr of cash reserves as of Dec 31. Company may hike B2C prices in some Indian cities from 4Q, it added
- Arkade Developers – Company will build 20,232 square meters at three new home redevelopment projects in the western suburbs of Mumbai. The projects are expected to generate a revenue of Rs2150cr
- Equitas Small Finance Bank – Company says that stress in microfinance is “finally showing early signs of stability.”\* “We expect the collection efficiency to improve in the fourth quarter” amid tighter lending discipline in the industry as well as from initiatives taken by ESFB itself. Equitas' total advances grew 3.6% q/q and 13.94% y/y, while deposits grew 2.2% q/q or 25.79% y/y
- Wardwizard Innovations- Company has signed a strategic memorandum of understanding with C4V to strengthen the development of battery technology

### Global Market Update

- European Market European stocks advanced on Monday as investors snapped up buoyant chip sector stocks. The yield on 30-year US Treasuries rose to the highest since 2023. In Europe, investors' focus will turn to inflation data for the euro-area and individual member nations due Monday and Tuesday. Both Germany and France Index gained 0.2% and 0.5% respectively while marginally decline UK Index.
- Asian Market - Asian markets started the first full week of 2025 on a shaky note as traders struggled to track a healthy run-up on Wall Street, with minds turning to Donald Trump's second presidency. Concerns about China's stuttering economy, the outlook for US interest rates and the wars in Ukraine and the Middle East were also causing a sense of uncertainty.

Co. Name	Close	Low	S2	S1	PP	R1	R2	High
NIFTY 50	23,616	23,552	23,215	23,415	23,753	23,953	24,291	24,090
ADANIENT	2,472	2,464	2,396	2,434	2,501	2,539	2,607	2,569
ADANIPTS	1,163	1,158	1,131	1,147	1,174	1,190	1,217	1,201
APOLLOHOSP	7,440	7,291	7,219	7,330	7,401	7,512	7,584	7,473
ASIANPAINT	2,270	2,257	2,206	2,238	2,289	2,321	2,372	2,340
AXISBANK	1,064	1,060	1,041	1,053	1,071	1,083	1,102	1,090
BAJAJ-AUTO	8,825	8,795	8,606	8,715	8,905	9,014	9,203	9,094
BAJAJFINSV	1,689	1,675	1,641	1,665	1,699	1,723	1,757	1,733
BAJFINANCE	7,370	7,317	7,146	7,258	7,429	7,541	7,712	7,600
BEL	282	281	273	278	285	290	297	293
BHARTIARTL	1,589	1,567	1,546	1,568	1,589	1,610	1,632	1,610
BPCL	286	284	276	281	289	294	302	297
BRITANNIA	4,797	4,773	4,714	4,756	4,815	4,856	4,915	4,874
CIPLA	1,488	1,480	1,463	1,475	1,492	1,505	1,522	1,509
COALINDIA	379	377	367	373	384	390	400	394
DRREDDY	1,353	1,334	1,322	1,337	1,349	1,365	1,377	1,361
EICHERMOT	5,246	5,188	5,100	5,173	5,261	5,335	5,423	5,350
GRASIM	2,458	2,446	2,395	2,427	2,477	2,509	2,559	2,528
HCLTECH	1,949	1,930	1,907	1,928	1,951	1,971	1,994	1,973
HDFCBANK	1,711	1,706	1,673	1,692	1,725	1,744	1,776	1,757
HDFCLIFE	608	603	589	598	613	622	636	627
HEROMOTOCO	4,198	4,188	4,116	4,157	4,228	4,269	4,341	4,300
HINDALCO	573	572	557	565	580	587	602	594
HINDUNILVR	2,380	2,362	2,329	2,355	2,387	2,412	2,444	2,419
ICICIBANK	1,266	1,257	1,246	1,256	1,267	1,277	1,288	1,278

Co. Name	Close	Low	S2	S1	PP	R1	R2	High
INDUSINDBK	970	963	938	954	979	996	1,021	1,005
INFY	1,939	1,928	1,902	1,920	1,947	1,965	1,992	1,973
ITC	445	441	429	437	449	458	470	462
JSWSTEEL	902	898	885	893	907	915	929	920
KOTAKBANK	1,778	1,773	1,740	1,759	1,792	1,811	1,844	1,825
LT	3,607	3,586	3,522	3,564	3,628	3,671	3,735	3,692
M&M	3,096	3,090	2,995	3,046	3,140	3,191	3,285	3,235
MARUTI	11,730	11,691	11,511	11,621	11,800	11,910	12,090	11,980
NESTLEIND	2,191	2,170	2,127	2,159	2,202	2,234	2,277	2,245
NTPC	328	326	317	322	332	337	347	342
ONGC	255	251	247	251	255	259	263	260
POWERGRID	307	305	298	302	309	314	321	317
RELIANCE	1,216	1,215	1,184	1,200	1,231	1,247	1,278	1,262
SBILIFE	1,438	1,425	1,404	1,421	1,442	1,458	1,479	1,463
SBIN	778	773	759	769	783	793	808	798
SHRIRAMFIN	2,972	2,955	2,877	2,924	3,003	3,051	3,129	3,081
SUNPHARMA	1,849	1,826	1,813	1,831	1,844	1,862	1,875	1,857
TATACONSUM	950	929	919	934	945	960	971	955
TATAMOTORS	776	765	747	762	780	794	812	798
TATASTEEL	132	131	127	129	134	136	141	138
TCS	4,090	4,066	4,019	4,054	4,102	4,138	4,185	4,150
TECHM	1,688	1,675	1,655	1,672	1,691	1,708	1,728	1,711
TITAN	3,477	3,441	3,395	3,436	3,482	3,523	3,569	3,529
TRENT	6,990	6,935	6,685	6,837	7,088	7,241	7,491	7,339
ULTRACEMCO	11,490	11,450	11,194	11,342	11,598	11,746	12,003	11,855
WIPRO	294	291	287	290	294	298	301	298

## Siddhartha Khemka Head - Retail Research

## Chandan Taparia, CMT, CFTe Derivatives & Technical Analyst

### Disclosures:

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on [www.motilaloswal.com](http://www.motilaloswal.com). MOFSL is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Ltd. are available on the website at <http://onlinereports.motilaloswal.com/Dormant/documents/Associate%20Details.pdf>

Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

MOFSL, it's associates, Research Analyst or their relatives may have any financial interest in the subject company. MOFSL and/or its associates and/or Research Analyst or their relatives may have actual beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance. MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may have any other potential conflict of interests at the time of publication of the research report or at the time of public appearance, however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report..

In the past 12 months, MOFSL or any of its associates may have:

- received any compensation/other benefits from the subject company of this report
- managed or co-managed public offering of securities from subject company of this research report,
- received compensation for investment banking or merchant banking or brokerage services from subject company of this research report,
- received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company of this research report.

- MOFSL and it's associates have not received any compensation or other benefits from the subject company or third party in connection with the research report.
- Subject Company may have been a client of MOFSL or its associates during twelve months preceding the date of distribution of the research report.
- Research Analyst may have served as director/officer/employee in the subject company.
- MOFSL and research analyst may engage in market making activity for the subject company.

MOFSL and its associate company(ies), and Research Analyst and their relatives from time to time may have:

a) a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein.

(b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

To enhance transparency, MOFSL has incorporated a Disclosure of Interest Statement in this document. This should, however, not be treated as endorsement of the views expressed in the report. MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report.

### Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

### Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

### Disclosure of Interest Statement

Analyst ownership of the stock No

A graph of daily closing prices of securities is available at [www.nseindia.com](http://www.nseindia.com), [www.bseindia.com](http://www.bseindia.com). Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to subject company for which Research Team have expressed their views.

### Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

### For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Financial Services Limited (SEBI Reg No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

### For U.S.

MOTILAL Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

### For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets Singapore Pte Ltd ("MOCMSPL") (Co.Reg. NO. 201129401Z) which is a holder of a capital markets services license and an exempt financial adviser in Singapore, as per the approved agreement under Paragraph 9 of Third Schedule of Securities and Futures Act (CAP 289) and Paragraph 11 of First Schedule of Financial Advisors Act (CAP 110) provided to MOCMSPL by Monetary Authority of Singapore. Persons in Singapore should contact MOCMSPL in respect of any matter arising from, or in connection with this report/publication/communication. This report is distributed solely to persons who qualify as "Institutional Investors", of which some of whom may consist of "accredited" institutional investors as defined in section 4A(1) of the Securities and Futures Act, Chapter 289 of Singapore ("the SFA"). Accordingly, if a Singapore person is not or ceases to be such an institutional investor, such Singapore Person must immediately discontinue any use of this Report and inform MOCMSPL.

### Disclaimer:

This report is intended for distribution to Retail Investors.

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; [www.motilaloswal.com](http://www.motilaloswal.com). Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: [na@motilaloswal.com](mailto:na@motilaloswal.com), Contact No.:022-40548085.

### Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	<a href="mailto:query@motilaloswal.com">query@motilaloswal.com</a>
Ms. Kumud Upadhyay	022 40548082	<a href="mailto:servicehead@motilaloswal.com">servicehead@motilaloswal.com</a>
Mr. Ajay Menon	022 40548083	<a href="mailto:am@motilaloswal.com">am@motilaloswal.com</a>

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN :. 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to [query@motilaloswal.com](mailto:query@motilaloswal.com). In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to [grievances@motilaloswal.com](mailto:grievances@motilaloswal.com), for DP to [dp grievances@motilaloswal.com](mailto:dp grievances@motilaloswal.com).